

E. Ray Dorsey, MD, MBA

CONTACT INFORMATION

265 Crittenden Blvd, CU 420694
Rochester, NY 14642
585.276.6824 office
585.461.4594 fax
ray.dorsey@chet.rochester.edu

EDUCATION AND TRAINING

1994 BS Stanford University, Stanford, CA; Biological sciences
1999 MD University of Pennsylvania School of Medicine, Philadelphia, PA
1999 MBA The Wharton School, University of Pennsylvania, Philadelphia, PA; Health care management

PROFESSIONAL EXPERIENCE

1993 Intern, U.S. Health Care Financing Administration (now the Centers for Medicare & Medicaid Services), Washington, DC
1995 Intern, Robert Wood Johnson Foundation, Princeton, NJ
1998 Investment banking summer associate, Health Care Group, Credit Suisse First Boston, Chicago, IL
1999-2001 Associate, McKinsey & Company, Chicago, IL
2001-02 Medicine intern, Evanston Hospital, Evanston Northwestern Healthcare, Evanston, IL
2002-05 Neurology resident, University of Pennsylvania Medical Center, Philadelphia, PA
2005-07 Fellow in movement disorders and experimental therapeutics, University of Rochester, Rochester, NY
2005-06 Instructor, Department of Neurology, University of Rochester, Rochester, NY
2006-07 Senior Instructor, Department of Neurology, University of Rochester, Rochester, NY
2007-10 Assistant Professor, Department of Neurology, University of Rochester, Rochester, NY
2010-2013 Associate Professor, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD
2010-2013 Director of movement disorders division, Johns Hopkins School of Medicine, Baltimore, MD
2010-2013 Director of neurology telemedicine, Johns Hopkins School of Medicine, Baltimore, MD
2011-2013 Associate Professor, Carey Business School, Johns Hopkins University, Baltimore, MD
2013-present Professor of Neurology, University of Rochester Medical Center, Rochester, NY
2013-2014 Co-director, Center for Health & Technology (CHeT), University of Rochester Medical Center, Rochester, NY
2014-present Director, CHeT, University of Rochester Medical Center, Rochester, NY
2014-present David M. Levy Professor in Neurology, University of Rochester Medical Center, Rochester, NY
2016-present Professor of Neurology with tenure, University of Rochester Medical Center, Rochester, NY
2017-present Medical director of telemedicine, University of Rochester Medical Faculty Group, University of Rochester Medical Center, Rochester, NY

RESEARCH ACTIVITIES

Peer-Reviewed Publications

1. **Dorsey ER**, Jarjoura D, Rutecki GW. Influence of controllable lifestyle on recent trends in specialty choice by US medical students. *JAMA* 2003;290:1173-8. Erratum in *JAMA* 2003;290:2666. [PMID: 12952999]
2. **Dorsey ER**, Jarjoura D, Rutecki GW. The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003. *Acad Med* 2005;80:791-6. [PMID: 16123455]
3. Moses H, **Dorsey ER**, Matheson DH, Thier SO. Financial anatomy of biomedical research. *JAMA* 2005;294:1333-42. [PMID: 16174691]
4. **Dorsey ER**, Nincic D, Schwartz JS. Costs of medical education: an evaluation of four approaches to reduce the financial burden of medical education. *Acad Med* 2006;81:245-51. [PMID: 16501266]
5. **Dorsey ER**, Holloway RG, Ravina BM. Biomarkers in Parkinson's disease. *Expert Rev of Neurotherapeutics* 2006;6:823-31. [PMID: 16784406]
6. **Dorsey ER**, Raphael BA, Balcer LJ, Galetta SL. Predictors of future publication record and academic rank in a cohort of neurology residents. *Neurology* 2006;67:1335-7. [PMID: 17060557]
7. **Dorsey ER**, Vitticore P, de Roulet J, Thompson JP, Carrasco M, Johnston SC, Holloway RG, Moses H. Financial anatomy of neuroscience research. *Ann Neurol* 2006;60:652-9. [PMID: 17192926]
8. **Dorsey ER**, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 – 2030. *Neurology* 2007;68:384-6. [PMID: 17082464]
9. **Dorsey ER**, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis. *Neurology* 2007;68:1524-8. [PMID: 17470756]
10. Thompson JP, Noyes K, **Dorsey ER**, Schwid SR, Holloway RG. A quantitative risk-benefit analysis of natalizumab. *Neurology* 2008;71:357-64. [PMCID: PMC2676947]
11. Oster E, **Dorsey ER**, Bausch J, Shinaman A, Kayson E, Oakes D, Shoulson I, Quaid K for the Huntington Study Group PHAROS Investigators. Fear of health insurance loss among individuals at risk for Huntington disease. *Am J Med Genet Part A* 2008;146A:2070-7. [PMCID: PMC2574833]
12. Mauldin PD, Guimaraes P, Albin RL, **Dorsey ER**, Bainbridge JL, Siderowf A for NINDS NET-PD Investigators. Optimal Frequency for Measuring Healthcare Utilization in Parkinson's Disease Using Participant Recall: The FS-TOO Resource Utilization Sub-Study. *Clinical Therapeutics* 2008;30:1553-7. [PMCID: PMC3773694]
13. Huntington Study Group TREND-HD Investigators (**Dorsey ER** – corresponding author). Randomized, controlled trial of ethyl-EPA in Huntington disease. *Arch Neurol* 2008;65:1582-9. [PMID: 19064745]
14. **Dorsey ER**, Beck CA, Adams M, Chadwick G, de Bleeck EA, McCallum C, Briner L, Deuel L, Clarke A, Stewart R, Shoulson I, and the Huntington Study Group TREND-HD Investigators. Communicating clinical trial results to research participants. *Arch Neurol* 2008;65:1590-5. [PMID: 19064746]
15. **Dorsey ER**, Van Wuyckhuse BC, Beck CA, Passalacqua WP, Guzik DS. Economics of new faculty hires in basic science. *Acad Med* 2009;84:26-31. [PMCID: PMC2746364]
16. **Dorsey ER**, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H. Funding of Parkinson research from industry and U.S. federal and foundation sources. *Movement Disorders* 2009;24:731-7. [PMID: 19133662]
17. Biglan KM, Voss TS, Deuel LM, Miller D, Eason S, Fagnano M, George BP, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, **Dorsey ER**. Telemedicine for the care of nursing home residents with Parkinson disease. *Movement Disorders* 2009;24:1073-1076. [PMID: 19353687]
18. **Dorsey ER**, Thompson JP, Dayoub E, George B, Saubermann LA, Holloway R. Selegiline shortage: causes and costs of a generic drug shortage. *Neurology* 2009;73:213-7. [PMCID: PMC2715573]
19. **Dorsey ER**, Thompson JP, Carrasco M, de Roulet J, Vitticore P, Nicholson S, Johnston SC, Holloway RG, Moses H, III. Financing and productivity of biomedical research across therapeutic areas. *PLoS One* 4(9): e7015. doi:10.1371/journal.pone.0007015. [PMCID: PMC2735780]
20. Mitumoto J, **Dorsey ER**, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. *Ann Neurol* 2009;66:184-90. [PMCID: PMC3785304]

21. **Dorsey ER**, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box warnings on atypical antipsychotic medication use. *Arch Intern Med* 2010;170:96-103. [PMID: 20065205]
22. **Dorsey ER**, de Roulet J, Thompson JP, Reminick JI, Thai A, White-Stellato Z, Beck CA, George BP, Moses H. Funding of US biomedical research, 2003 – 2008. *JAMA* 2010;303:137-43. [PMCID: PMC3118092]
23. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, **Dorsey ER**, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A and the DIMOND Investigators of the Huntington Study Group. A randomized, placebo-controlled trial of latrepiridine in Huntington disease. *Arch Neurol* 2010;67:154-60. [PMID: 20142523]
24. Block RC, **Dorsey ER**, Beck CA, Brenna JT, Shoulson I. Altered cholesterol and fatty acid metabolism in Huntington disease. *Journal of Clinical Lipidology* 2010;4:17-23. [PMCID: PMC2926984]
25. Ravina B, Deuel LM, Siderowf A, **Dorsey ER**. Local IRB review of a multicenter trial: local costs without local context. *Ann Neurol* 2010;67:258-60. [PMCID: PMC2848288]
26. **Dorsey ER**, Deuel LM, Voss TS, Finnigan K, George BP, Eason S, Miller D, Reminick J, Appler A, Polanowicz J, Viti L, Smith S, Joseph A, Biglan KM. Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson disease. *Movement Disorders* 2010;25:1652-9.
27. **Dorsey ER**, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM. A U.S. survey of patients with Parkinson disease: satisfaction with medical care and support groups. *Movement Disorders* 2010;25:2128-35. [PMID 20533449]
28. Oster E, Shoulson I, Quaid K, **Dorsey ER** on behalf of the Huntington Study Group PHAROS Investigators. Genetic adverse selection: evidence from long-term care insurance and Huntington disease. *Journal of Public Economics* 2010;94:1041-50.
29. Gillum LA, Gouveia C, **Dorsey ER**, Pletcher M, Mathers CD, McCulloch CE, Johnston SC. NIH disease funding levels and burden of disease. *PLoS One* 2011;6:e16837. [PMCID: PMC3044706]
30. **Dorsey ER**, Deuel LM, Beck CA, Gardiner IF, Scoglio NJ, Scott JC, Marshall FJ, Biglan KM. Group patient visits for Parkinson disease: a randomized feasibility trial. *Neurology* 2011;76:1542-7. [PMCID: PMC3100128]
31. **Dorsey ER**, George BP, Dayoub EJ, Ravina BM. Finances of the publishers of the most highly cited US medical journals. *JMLA* 2011;99:255-8. [PMCID: PMC3133891]
32. Sotirchos ES, **Dorsey ER**, Tan IL, Zee DS. Opsoclonus-myoclonus syndrome and exaggerated startle response associated with small-cell lung cancer. *Movement Disorders* 2011;26:1769-70. [PMCID: PMC3139745]
33. Probasco JC, Felling RJ, Carson JT, **Dorsey ER**, Niessen TM. Teaching NeurolImages: Myelopathy due to B12 deficiency in long-term colchicine treatment and nitrous oxide misuse. *Neurology* 2011;77:e51.
34. **Dorsey R**, Biglan K, Eberly S, Auinger P; Brocht A; Umeh CC; Oakes D, Clarence-Smith K, Marshall F, Shoulson I, Frank S. Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study [Internet]. Version 19. *PLoS Currents: Huntington Disease*. 2011 Oct 24. Available from: <http://knol.google.com/k/ray-dorsey/use-of-tetrabenazine-in-huntington/xzu6cpdljzr7/1>.
35. Garfield CF, **Dorsey ER**, Zhu S, Huskamp HA, Conti R, Dusetzina SB, Higashi A, Perrin JM, Kornfield R, Alexander GC. Trends in attention deficit hyperactivity disorder: ambulatory diagnosis and medical treatment in the United States, 2000-2010. *Academic Pediatrics* 2012;12:110-116. [PMCID: PMC3307907]
36. Higashi AS, Dusetzina SB, **Dorsey ER**, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. *Medical Care* 2012;50:466-78 [PMCID: PMC3342472]
37. Huntington Study Group COHORT Investigators (**Dorsey ER** – corresponding author; Shoulson I – principal investigator). Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. *PLoS One* 2012;7:e29522. [PMCID: PMC3281013]
38. Shprecher DS, Noyes K, Biglan K, Wang D, **Dorsey ER**, Kurlan R, Adams MJ. Willingness of Parkinson disease patients to participate in research using Internet-based technology. *Telemedicine and e-Health* 2012;18:684-7. [PMCID: PMC3491628]

39. Biglan KM, **Dorsey ER**, Evans RVV, Ross CA, Hersch S, Shoulson I, Matson W, Kiebertz K for the Huntington Study Group Pre2CARE Investigators. Plasma 8-hydroxy-2'-deoxyguanosine levels in Huntington disease and healthy controls treated with coenzyme Q₁₀. *Journal of Huntington's Disease* 2012;1:65-69.
40. George BP, Scoglio NJ, Reminick JI, Rajan B, Beck CA, Seidmann A, Biglan KM, **Dorsey ER**. Telemedicine in leading U.S. neurology departments. *Neurohospitalist* 2012;2:123-8. [PMCID: PMC3726111]
41. Moses H III, **Dorsey ER**. Biomedical research in an age of austerity. *JAMA* 2012;308:2341-2.
42. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S ... **Dorsey ER** ... Lopez AD. Disability-adjusted life years for 291 causes, 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2197-2223.
43. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V ... **Dorsey ER** ... Lopez AD, Murray CJ. Global and regional mortality from 235 causes of death for 20 age-groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095-2128.
44. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S ... **Dorsey ER** ... Lopez AD, Murray CJ. Years lived with disability for 1,160 sequelae of 291 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study. *Lancet* 2012;380:2163-96.
45. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V ... **Dorsey ER** ... Murray CJ. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2129-43.
46. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H ... **Dorsey ER** ... Lopez AD, Murray CJ, Ezzati M. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2224-60. [PMCID:PMC4156511]
47. Horizon Investigators of the Huntington Study Group and European Huntington's Disease Network (**Dorsey ER** – corresponding author). A randomized, double-blind, placebo-controlled study of latrepidine in individuals with mild to moderate Huntington disease. *JAMA Neurology* 2013;70:25-33.
48. Abdolahi A, Scoglio N, Killoran A, **Dorsey ER**, Biglan KM. Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. *Parkinsonism Relat Disord* 2013;19:218-21. [PMCID: PMC3666325]
49. Kornfield R, Watson S, Higashi A, Conti RM, Dusetzina SB, Garfield CF, **Dorsey ER**, Huskamp HA, Alexander GC. Effects of FDA advisories on the pharmacologic treatment of Attention Deficit Hyperactivity Disorder. *Psychiatric Services* 2013;64:339-46. [PMCID: PMC4023684]
50. Oster E, Shoulson I, **Dorsey ER**. Optimal expectations and limited medical testing: evidence from Huntington disease. *American Economic Review* 2013;103:804-30.
51. **Dorsey ER**, Venkataraman V, Grana MJ, Bull MT, George BP, Boyd CM, Beck CA, Rajan B, Seidmann A, Biglan KM. Randomized, controlled trial of “virtual housecalls” for Parkinson disease. *JAMA Neurology* 2013;70:565-70. [PMCID:PMC3791511]
52. **Dorsey ER**, George BP, Leff B, Willis AW. The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. *Neurology* 2013;80:1989-96. [PMCID: PMC3716348]
53. US Burden of Disease Collaboration (Murray CJ – corresponding author; **Dorsey ER** – co-author). The state of US health: burden of diseases, injuries and risk factors 1990 to 2010. *JAMA* 2013;310:591-608.
54. Oster E, Shoulson I, **Dorsey ER**. Limited life expectancy, human capital and health investments. *American Economic Review* 2013;103:1977-2002.
55. Moses III H, Matheson DHM, **Dorsey ER**, George BP, Sadoff D, Yoshimura S. The anatomy of health care in the United States. *JAMA* 2013;310:1947-63.
56. **Dorsey ER**, Darwin K, Nichols P, Kwok J, Bennet C, Rosenthal L, Bombard Y, Shoulson S, Oster E. Knowledge of the Genetic Information Nondiscrimination Act among individuals affected by Huntington disease. *Clinical Genetics* 2013 Sep;84(3):251-7.

57. **Dorsey ER**, Beck CA, Darwin K, Nichols P, Brocht AFD, Biglan KM, Shoulson I, on behalf of the Huntington Study Group COHORT Investigators. Natural history of Huntington disease. *JAMA Neurology* 2013 Dec;70(12):1520-30.
58. Rajan B, **Dorsey ER**, Seidmann A. The competitive business impact of using telemedicine for the treatment of patients with chronic conditions. *Journal of Management Information Systems* 2013;30:127-57.
59. **Dorsey ER**, Brocht AFD, Nichols PE, Darwin KC, Anderson KE, Beck CA, Singh S, Biglan KM, Shoulson I. Depressed mood and suicidality in individuals exposed to tetrabenazine in a large Huntington disease observational study. *Journal of Huntington's Disease* 2013;2:509-15.
60. Probasco JC, George BP, **Dorsey ER**, Venkatesan A. Neurohospitalists: perceived need and training requirements in academic neurology. *Neurohospitalist* 2014 January; 4(1): 9-17. [PMCID: PMC3869308]
61. Venkataraman V, Donohue SJ, Biglan KM, Wicks P, **Dorsey ER**. Virtual visits for Parkinson disease: a case series. *Neurology: Clinical Practice* 2014 Apr;4(2):146-152. [PMCID: PMC4001180]
62. Achey M, Aldred JL, Aljehani N, Bloem BR, Biglan KM, Chan P, Cubo E, **Dorsey ER** (corresponding author), Goetz CG, Guttman M, Hassan A, Khandhar SM, Mari Z, Spindler M, Tanner CM, van den Haak P, Walker R, Wilkinson R (International Parkinson and Movement Disorder Society Telemedicine Task Force). The past, present, and future of telemedicine for Parkinson disease. *Mov Disord* 2014;29: 871–883.
63. George BP, Probasco JC, **Dorsey ER**, Venkatesan A. Impact of 2011 resident duty hour requirements on neurology residency programs and departments. *Neurohospitalist* 2014;4:119-26. [PMCID: PMC4056414]
64. Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, **Dorsey ER**, Biglan KM. A pilot study of virtual visits in Huntington disease. *J Huntington Dis*. 2014;3:189-195.
65. George BP, Venkataraman V, **Dorsey ER**, Johnston SC. Impact of alternative medical device approval process on costs and health. *Clinical and Translational Science* 2014;3:368-75. [PMCID: PMC4213282]
66. Abdolahi A, Bull MT, Darwin KC, Venkataraman V, Grana MG, **Dorsey ER**, Biglan KM. A pilot feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders. *Health Informatics Journal* 2014 (epub ahead of print).
67. Achey MA, Beck CA, Beran DB, Boyd CM, Schmidt PN, Willis AW, Riggare SS, Simone RB, Biglan KM, **Dorsey ER**. Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. *Trials* 2014;15:465. [PMCID: PMC4289172] Erratum *Trials* 2016;17:7. [PMCID: PMC4700612]
68. Huntington Study Group Reach2HD Investigators (corresponding author – **Dorsey ER**). Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Neurology* 2015;385:117-71. doi 10.1016/S0140-6736(14)61682.2
69. Moses III H, Matheson DHM, Cairns-Smith S, George BP, Palisch C, **Dorsey ER**. The anatomy of medical research. *JAMA* 2015;313:174-89.
70. **Dorsey ER**, Venuto C, Harris D, Venkataraman V, Kiebertz K. Novel methods & technologies for 21st century clinical trials. *JAMA Neurology* 2015;72:582-8. [PMCID: PMC4708881]
71. Daschle T, **Dorsey ER**. The return of the house call. *Ann Int Med* 2015;162:587-8. doi: 10.7326/M14-2769
72. GBD 2013 Mortality and Causes of Death Collaborators (**Dorsey ER** – co-author). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis of the Global Burden of Disease Study 2013. *Lancet* 2015;385:117-71.[PMCID: PMC4340604]
73. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (Gusella J – corresponding author; **Dorsey ER** – co-author). Identification of genetic factors that may modify clinical onset of Huntington's disease. *Cell* 2015;162:516-26. [PMCID: PMC4524551]
74. Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, **Dorsey ER**, Little MA. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: a pilot study. *Parkinsonism and Related Disorders* 2015;21:650-3.
75. Bates G, **Dorsey R**, Gusella J, Hayden M, Kay C, Leavitt B, Nance M, Ross C, Scahill R, Wetzel R, Wild E, Tabrizi S. Huntington's disease. *Nature Reviews Disease Primer* 1, 15005 (2015). doi: 10.1038/nrdp.2015.5.

76. Safarpour D, Thibault DP, DeSanto C, Boyd C, **Dorsey ER**, Racette BA, Willis AW. Nursing home and end-of-life care in Parkinson disease. *Neurology* 2015;85:413-9. [PMCID: PMC4534080]
77. **Dorsey ER**, Wagner JD, Bull MT, Rizzieri A, Grischkan J, Achey MA, Sherer T, Chowdury S, Meunier C, Cappelletti L, Rocker C, Richard IH, Schwarz H, Kang G, Ahmad SH, Biemiller RA, Biglan KM. Feasibility of virtual research visits in Fox Trial Finder. *Journal of Parkinson's disease* 2015;5:505-15.
78. George BP, Asemota AO, **Dorsey ER**, Haider AH, Smart BJ, Urrutia VC, Schneider EB. United States trends in thrombolysis for older adults with acute ischemic stroke. *Clinical neurology and neurosurgery*. 2015;139:16-23.
79. GBD 2013 Risk Factor Collaborators (**Dorsey ER** – co-author). Global, regional, and national comparative risk assessments of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:2287-323. [PMCID: PMC4685753]
80. Oster E, Eberly SW, **Dorsey ER**, Kayson-Rubin E, Oakes D, Shoulson I. Informativeness of early Huntington disease signs about gene status. *J Huntington Disease* 2015;4:271-7.
81. **Dorsey ER**, Darwin KC, Mohammed S, Donohue S, Tethal A, Achey MA, Ward S, Caughey E, Conley ED, Eriksson N, Ravina B. Virtual research visits and direct-to-consumer genetic testing in Parkinson's disease. *Digital Health* Jun 2015, doi: 10.1177/2055207615592998.
82. Global Burden of Disease Study 2013 Collaborators (**Dorsey ER** – co-author). Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015;386:743-800. [PMCID: PMC4561509]
83. Global Burden of Disease 2013 DALYs and HALE Collaborators (**Dorsey ER** – co-author). Global, regional, and national disability-adjusted life years for 306 diseases and injuries and healthy life expectancy for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet* 2015;386:2145-91. [PMCID: PMC4673910]
84. **Dorsey ER**, Ritzer G. The McDonaldization of medicine. *JAMA Neurology* 2016;73:15-6.
85. Bot BM, Suver C, Neto ED, Kellen M, Klein A, Bare C, Doerr M, Pratap A, Wilbanks J, **Dorsey ER**, Friend SH, Trister AD. The mPower study, Parkinson disease mobile data collected using ResearchKit. *Nature Scientific Data* 2016;3:160011; doi: 10.1038/sdata.2016.11
86. Connect.Parkinson Investigators (**Dorsey ER** – corresponding author). National randomized controlled trial of virtual house calls for people with Parkinson disease: interest and barriers. *Telemedicine and e-health* 2016;22:590-8.
87. **Dorsey ER**, Topol EJ. The state of telehealth. *NEJM* 2016;375:154-61.
88. Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, Cai H, Reilmann R, Little MA, Gwin JT, Biglan KM, **Dorsey ER**. Wearable sensors in Huntington disease: a pilot study. *Journal of Huntington's Disease* 2016;5:199-206.
89. Espay AJ, Bonato P, Nahab FB, Maetzler W, Dean JM, Klucken J, Eskofier BM, Merola A, Horak F, Lang AE, Reilmann R, Giuffrida J, Nieuwboer A, Horne M, Little MA, Litvan I, Simuni T, **Dorsey ER**, Burack MA, Kubota K, Kamondi A, Godinho C, Daneault JF, Mitsi G, Krinke L, Hausdorff JM, Bloem BR, Papapetropoulos S; Movement Disorders Society Task Force on Technology. Technology in Parkinson disease: challenges and opportunities. *Movement Disorders* 2016;31:1272-82.
90. Augustine ER, **Dorsey ER**, Hauser RA, Elm JJ, Tilley BC, Kieburtz KK. Communicating with participants during the conduct of multi-center clinical trials. *Clinical Trials* 2016;13:592-6.
91. Friedman AB, Grischkan JA, **Dorsey ER**, George BP. Forgiven but not relieved: US physician workforce consequences of changes to public service loan forgiveness. *JGIM* 2016;31:1237-41.
92. **Dorsey ER**, Vlaanderen FP, Engelen LJPG, Kieburtz K, Zhu W, Biglan KM, Farber MJ, Bloem BR. Moving Parkinson care to the home. *Movement Disorders* 2016;31:1258-62.

93. Thibault D, Weintraub D, **Dorsey ER**, Schmidt P, Willis AW. Hospital care for mental health and substance abuse conditions in Parkinson disease. *Movement Disorders* 2016;31:1810-9. doi: 10.1002/mds.26832.
94. GBD 2015 SDG Collaborators (**Dorsey ER** – co-author). Measuring the health-related sustainable development goals in 188 countries: a baseline analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1813-50.
95. GBD 2015 Risk Factors Collaborators (**Dorsey ER** – co-author). Global, regional, and national comparative risk assessment of 79 behavioural, environmental, occupational, and metabolic risk or clusters of risks, 1990-2015: a systematic analysis of the Global Burden of Disease Study 2015. *Lancet* 2016;388:1659-1724.
96. Venuto CS, Potter NB, **Dorsey ER**, Kiebertz K. A review of disease progression models of Parkinson's disease and applications in Clinical Trials. *Movement Disorders* 2016;31:947-56.
97. **Dorsey ER**, Chan YY, McConnell MV, Shaw SY, Trister AD, Friend SH. The use of smartphones for health research. *Academic Medicine* 2017;92:157-60.
98. Rosenthal L, Mills K, Pantelyat A, Mari, Z, Wang J, Pontone G, **Dorsey ER**, Wang J, Wu SS, Mari Z. Changes in verbal fluency in Parkinson's disease. *Movement Disorders Clinical Practice* 2017;4:84-89. doi: 10.1002/mdc3.12421
99. George BP, **Dorsey ER**, Grischkan JA. Loan forgiveness options for young neurologists: current landscape and practice implications. *Neurology* 2017;88:e153-6. doi: 10.1212/WNL.0000000000003817.
100. Augustine ER, **Dorsey ER**, Saltonstall P. The care continuum – an evolving model for care and research in rare diseases. *Pediatrics* (in press).
101. Korn RE, Shukla AW, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, **Dorsey ER**, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis N. Virtual visits for Parkinson disease: a multi-center non-controlled cohort. *Neurology Clinical Practice* (in press).
102. Hirsch IB, Martinez J, **Dorsey ER**, Finken G, Fleming A, Gropp C, Home P, Kaufer DI, Papapetropoulos S. Incorporating site-less clinical trials into drug development: a framework for action. *Clin Ther* 2017 (epub ahead of print). doi : 10.1016/j.clinthera.2017.03.018.
103. GBD 2015 Healthcare Access and Quality Collaborators (**Dorsey ER** – co-author). Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. *Lancet* 2017 (epub ahead of print). doi: 10.1016/S0140-6736(17)30818-8
104. Heldman DA, Harris DA, Felong T, Andrzejewski KL, **Dorsey ER**, Giuffrida JP, Goldberg B, Burack MA. Telehealth management of Parkinson's disease using wearable sensors: an exploratory study. *Digit Biomark* (epub ahead of print). doi: 10.1159/000475801.
105. Beck CA, Beran DB, Biglan KM, Boyd CM, **Dorsey ER**, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. *Neurology* (in press).
106. Mammen JR, Elson MJ, Java JJ, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, **Dorsey ER**. Patient and physician perceptions of virtual visits for Parkinson disease: a qualitative study. *Telemedicine and e-Health* (in press).
107. Grischkan J, George BP, Chaiyachati K, Friedman AB, **Dorsey ER**, Asch CA. Distribution of medical education debt by specialty. *JAMA Internal Medicine* (in press).
108. Adams JL, Dinesh K, Xiong M, Tarolli CG, Sharma S, Sheth N, Aranyosi AJ, Zhu W, Goldenthal S, Biglan KM, **Dorsey ER**, Sharma G. Multiple wearable sensors in Parkinson and Huntington disease: a pilot study in clinic and at home. *Digit Biomark* (in press).

109. **Dorsey ER**, Papapetropoulos S, Xiong M, Kiebertz K. The first frontier: digital biomarkers for neurodegenerative disorders. Digit Biomark (in press)
110. Purks JL, Wilhelm EE, Shoulson I, Creveling J, **Dorsey ER**, Irony T, LoCastro TM, Pagan F, Ravina B, Simuni T, Sterling M, Tariot P, Anderson KE. Inaugural Conference on Incorporating Patient-Reported Outcomes and Patient Preference Information into Clinical Research, Clinical Care, and Risk-Benefit Assessments for Neurodegenerative Diseases. Patient 2017 (epub ahead of print). doi: 10.1007/s40271-017-0257-5.
111. GBD 2015 Healthcare Access and Quality Collaborators (**Dorsey ER** – co-author). Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet 2017 (epub ahead of print). doi: 10.1016/S0140-6736(17)30818-8.

Extramural Funding

CURRENT

5/1/17 – 5/1/19	Patient-Centered Outcomes Research Institute Direct cost: \$300,000 This contract will support a refinement, implementation, and dissemination of telemedicine care model for individuals with Parkinson disease. Role: Principal investigator
2/8/11 – 2/8/18	Michael J. Fox Foundation (PI – Tarolli) Direct cost: \$100,000 This grant supports a one-time remote evaluation of individuals with atypical parkinsonian disorders, Role: Co-principal investigator
9/1/16 – 8/31/21	Burroughs Wellcome Fund – Innovation in Regulatory Science Direct cost: \$500,000 This Innovation in Regulatory Science Award will help support the implementation of a smartphone research application (mPower) into a phase 3 clinical trial in Parkinson disease. Role: Principal investigator
7/1/16 – 12/31/18	Safra Foundation Direct cost: \$400,000 This grant in conjunction with support from the Greater Rochester Health Foundation will enable us to provide care remotely to ~500 individuals with Parkinson disease throughout New York state for free (Parkinson Disease Care, New York). Role: Principal investigator
7/1/16 – 6/30/19	Greater Rochester Health Foundation (PI – Biglan) Direct cost: \$400,000 This grant in conjunction with support from the Safra Foundation will enable us to provide care remotely to ~500 individuals with Parkinson disease throughout New York state for free (Parkinson Disease Care, New York). Role: Co-principal investigator
10/1/16 – 10/1/17	AbbVie Direct cost: \$100,000

This support will enable us to deliver educational content as part of our Parkinson Disease Care, New York initiative.
Role: Principal investigator

9/1/15 – 9/1/17

National Institute of Neurological Disorders and Stroke (1 P20 NS092529-01)

Direct cost: \$500,000

This P20 grant will evaluate new methodologies and tools including disease modelling, virtual research visits, and smartphones for conducting clinical research in Parkinson disease as part of a planning grant for a possible future Udall Center for Parkinson's research.

Role: Principal investigator

1/1/15 – 12/31/17

AMC Health

Direct cost: \$50,000

This study will examine the feasibility, reliability, and value of virtual research visits within a phase III clinical trial in Parkinson disease.

Role: Principal investigator

9/1/13 – 7/1/18

Michael J. Fox Foundation (PI – Kiebertz)

Direct cost: ~\$1,000,000 (clinical core)

The Parkinson's Progression Markers Initiative aims to identify biological markers of disease progression in Parkinson disease that can be used in future clinical trials of novel therapeutics.

Role: Clinical core investigator

5/1/14 – 5/1/18

Huntington Study Group

Direct cost: \$80,000

The Huntington Study Group provides support for serving as chair of the global research network.

Role: Chair

COMPLETED

1/1/15 – 12/31/16

Roche

Direct cost: \$90,000

This study will examine the changes in outcome measures in Huntington disease to inform the formation of a possible composite outcome for use in clinical trials.

Role: Principal investigator

8/1/13 – 3/1/17

Patient-Centered Outcomes Research Institute

Direct cost: \$1,300,000

This contract will support a national randomized controlled trial of telemedicine aimed at providing care to individuals with Parkinson disease with limited access to care.

Role: Principal investigator

7/1/15 – 12/31/16

Teva Pharmaceuticals

Direct cost: ~\$100,000

This research examines the natural history of the change in total motor score in Huntington disease.

Role: Principal investigator

1/1/16 – 12/31/16

Raptor Pharmaceuticals

	<p>Direct cost: \$50,000</p> <p>This study will examine the change in total motor score for subsets of individuals with Huntington disease.</p> <p>Role: Principal investigator</p>
11/1/15 – 11/30/16	<p>Auspex Pharmaceuticals</p> <p>Direct cost: \$50,000</p> <p>This study will investigate the feasibility and value of wearable sensors in the objective assessment of Huntington disease.</p> <p>Role: Principal investigator</p>
9/1/13 – 7/31/16	<p>Davis Phinney Foundation</p> <p>Direct cost: \$100,000</p> <p>This grant will evaluate the feasibility and benefits of conducting 250 virtual visits for individuals with Parkinson disease in five states.</p> <p>Role: Principal investigator</p>
1/1/15 – 12/31/15	<p>National Science Foundation (PI – Kautz)</p> <p>Direct cost: \$110,000</p> <p>This research aims to develop and evaluate a smart phone application for tracking contacts of individuals with potentially infectious conditions in West Africa.</p> <p>Role: Co-investigator</p>
7/1/14 – 9/30/15	<p>Great Lakes Neurotechnologies</p> <p>Direct cost: \$50,000</p> <p>This study will investigate the feasibility and value of in-home objective motor assessments in Parkinson disease.</p> <p>Role: Principal investigator</p>
7/1/14 – 6/30/15	<p>Sage Bionetworks</p> <p>Direct cost: \$100,000</p> <p>This study supports the development of a smartphone application for Parkinson disease.</p> <p>Role: Principal investigator</p>
9/1/13 – 9/1/14	<p>Michael J. Fox Foundation (PI – Biglan)</p> <p>Direct cost: \$100,000</p> <p>This study will examine the feasibility, reliability, and interest of virtual research visits among participants in the Fox Trial Finder.</p> <p>Role: Co-principal investigator</p>
11/1/11 – 9/30/14	<p>Prana Biotechnology</p> <p>Direct costs: \$3,800,000</p> <p>The objective is to conduct a phase II study evaluating the safety and tolerability, clinical outcomes, and effects of biomarkers of PBT2 in individuals with mild to moderate Huntington disease.</p> <p>Role: Principal investigator</p>
3/1/13 – 6/30/14	<p>Biogen</p> <p>Direct cost: \$59,000</p> <p>This grant will support the remote evaluation and assessment of individuals nationally with Parkinson disease who have previously undergone genetic testing via 23andMe.</p> <p>Role: Principal investigator</p>
11/1/12 – 11/1/13	<p>Verizon Foundation</p> <p>Direct costs: \$50,000</p> <p>This funding supports a global telemedicine clinic that provides free one-time consultations via web-based video conferencing to individuals with Parkinson disease.</p>

6/1/12 – 1/31/13	<p>Role: Principal Investigator</p> <p>Lundbeck (PI – Biglan)</p> <p>Direct costs: \$100,000</p> <p>This study aims to determine the feasibility, reliability, and validity of conducting assessments for Huntington disease via web-based video conferencing in the home.</p> <p>Role: Co-investigator</p>
10/1/12 – 8/1/13	<p>National Institute of Neurological Disorders and Stroke 1U01NS082133 (PI – Dawson)</p> <p>Direct costs: \$2,000,000</p> <p>This discovery effort utilizes sensitive mass spectrometry techniques to identify potential biomarkers in the blood and cerebrospinal fluid in Parkinson disease.</p> <p>Role: Collaborator</p>
1/1/12 – 8/1/13	<p>Macklin Foundation</p> <p>Direct costs: \$600,000</p> <p>The philanthropic funding supports the Ataxia Center at Johns Hopkins aimed at caring for patients with and advancing understanding of ataxia.</p> <p>Role: Interim director (principal investigator) of the Ataxia Center</p>
3/1/13 – 8/1/13	<p>Medtronic</p> <p>Direct cost: \$10,000</p> <p>This funding will help support outreach to expand telemedicine and access to care for people with Parkinson disease throughout the country.</p> <p>Role: Principal investigator</p>
12/1/12 – 8/1/13	<p>Avid Radiopharmaceuticals (PI – Wong)</p> <p>Direct costs: \$60,000</p> <p>This research is to evaluate a new radiopharmaceutical to assist in the diagnosis of Parkinson disease.</p> <p>Role: Co-investigator</p>
12/1/11 – 8/1/12	<p>Lundbeck</p> <p>Direct costs: \$200,000</p> <p>The research will investigate the natural history of Huntington disease, the treatment of chorea, and the safety of tetrabenazine.</p> <p>Role: Principal investigator</p>
10/1/10 – 7/31/13	<p>Agency for Health Care Research and Quality 1 R01 HS018960-01 (PI – Alexander)</p> <p>Direct costs: \$1,130,000</p> <p>The research will assess the effect of FDA safety advisories for approved drugs on provider, patient, and firm behavior.</p> <p>Role: Co-investigator</p>
10/1/10 – 12/31/12	<p>Google</p> <p>Direct costs: \$57,000</p> <p>The research will compare the effectiveness of providing care to patients with Parkinson disease in clinic to care in their homes via web-based video conferencing.</p> <p>Role: Principal investigator</p>
10/1/10 – 12/31/12	<p>Excellus BlueCross BlueShield</p> <p>Direct costs: \$20,000</p> <p>The research will compare the effectiveness of providing care to patients with Parkinson disease in clinic to care in their homes via web-based video conferencing.</p> <p>Role: Principal investigator</p>
5/1/11 – 11/1/11	<p>Lundbeck</p> <p>Direct costs: \$100,000</p>

The objective of the study was to study the safety and efficacy of tetrabenazine in different sub-populations of individuals with Huntington disease.
 Role: Principal investigator
 3/15/09 – 3/15/11 **Medivation, Inc. (PI – Kieburztz)**
 Direct costs: \$2,195,025
 The objective is to conduct a phase III randomized, controlled trial of dimebon to assess its safety and efficacy in 350 individuals with Huntington disease.
 Role: Steering committee member
 7/1/08 – 6/30/11 **Robert Wood Johnson Foundation**
 Direct costs: \$298,981
 As part of the Physician Faculty Scholars Program, the research will examine the influence of the genetic risk of Huntington disease on important life decisions.
 Role: Principal Investigator
 5/1/08 – 10/31/10 **Presbyterian Home for Central New York**
 Direct costs: \$80,000
 The purpose of the study is to evaluate the feasibility of telemedicine for nursing home residents with Parkinson disease residing far from an academic medical center.
 Role: Principal investigator
 4/1/08 – 3/31/11 **National Institutes of Health 1R01NS060118-01A1 (PI – Ross)**
 Direct costs: \$1,240,785
 The purpose of this clinical trial is to select a dosage of coenzyme Q₁₀ for future definitive randomized placebo controlled trials in pre-manifest Huntington disease.
 Role: Steering committee member
 7/1/07 – 6/30/11 **Cooperative Huntington's Observational Research Trial (PI – Shoulson)**
CHDI Foundation, Inc.
 Direct costs: \$3,620,128
 The objective of this longitudinal observational study is to collect phenotypic and genotypic data from individuals who are part of a Huntington disease family.
 Role: Clinical monitor and steering committee member
 9/1/07 – 8/31/11 **American Parkinson Disease Association Research Grant**
 Direct costs: \$50,000
 The aim is to estimate the current and to project the future number of people with Parkinson disease worldwide.
 Role: Principal investigator
 6/30/07 – 8/9/10 **National Institutes of Health 1 KL2 RR024136-01**
University of Rochester Clinical and Translational Science Award
KL2 Mentored Career Development Award
 Direct costs: \$380,000
 The aims of this career development award are to quantify biomedical research investment, to identify the resulting therapeutic advances, and to identify means to improve the productivity of research.
 Role: Principal investigator
 7/1/06 – 6/30/10 **National Parkinson Foundation Center of Excellence – Research Grant**
 Direct costs: \$230,000
 The goal of the research is to conduct a pilot, randomized controlled trial of group visits for individuals with Parkinson disease.
 Role: Principal investigator
 6/1/08 – 3/31/09 **Michael J. Fox Foundation for Parkinson's Research (PI – Ravina)**

	<p>Direct costs: \$15,598</p> <p>The aim is to quantify the economic costs, to evaluate benefits, and suggest improvements to local institutional review board review of multi-center clinical trials.</p> <p>Role: Co-principal investigator</p>
10/1/08 – 12/1/08	<p>Medivation, Inc.</p> <p>Direct costs: \$18,000</p> <p>The objective is to evaluate the relative strengths and weaknesses of cognitive outcome measures in Huntington disease clinical trials.</p> <p>Role: Principal investigator</p>
9/1/07 – 3/31/08	<p>Medivation, Inc. (PI – Kieburztz)</p> <p>Direct costs: \$1,788,613</p> <p>The objective is to conduct a phase II randomized, controlled trial of dimebon to assess its safety and tolerability and secondarily, its cognitive effects in Huntington disease.</p> <p>Role: Site principal investigator</p>
7/1/07 – 6/30/08	<p>Dean's Teaching Fellow Program, University of Rochester</p> <p>Direct costs: \$15,000 (declined financial support)</p> <p>The purpose of the research is to address the unmet educational needs of fellows by improving their communication skills and creating metrics to measure development.</p> <p>Role: Fellow/principal investigator</p>
6/1/07 – 3/31/08	<p>Michael J. Fox Foundation for Parkinson's Research</p> <p>Direct costs: \$20,000</p> <p>The purpose is to quantify research support for Parkinson disease and to determine the current state of therapeutic development for Parkinson disease.</p> <p>Role: Principal investigator</p>
7/1/06 – 6/30/08	<p>American Academy of Neurology Clinical Research Training Fellowship</p> <p>Direct costs: \$130,000</p> <p>The goal is to quantify neuroscience research funding and to determine the scientific and therapeutic advances that have resulted from that investment.</p> <p>Role: Principal investigator</p>
6/1/05 – 3/31/08	<p>Amarin Neuroscience Ltd (PI – Shoulson)</p> <p>Direct costs: \$4,396,094</p> <p>The objective is to conduct a phase III, multi-center, randomized controlled trial of ethyl-EPA, an omega-3 fatty acid in Huntington disease.</p> <p>Role: Medical monitor and steering committee member</p>
7/1/89 – 6/30/10	<p>National Institutes of Health T32 NS 07338-11 (PI – Griggs)</p> <p>Experimental Therapeutics of Neurological Disorders</p> <p>Direct costs: \$1,246,850</p> <p>The major goals of this project are to train clinical neuroscientists in design and conduct of clinical research in neurological disorders.</p> <p>Role: Experimental Therapeutics Fellow (7/05 – 6/07) Fellowship Director (7/07 – 3/10)</p>

Research Program Leadership

2005-08	Medical monitor and steering committee member, randomized controlled trial of ethyl-EPA for Huntington disease (TREND-HD)
2007-08	Site investigator, randomized controlled trial of dimebon for Huntington disease (DIMOND B)
2007-09	Principal investigator, randomized controlled trial of group patient visits for Parkinson disease (GROUP-PD)

2008	Principal investigator, pilot, randomized, controlled trial of telemedicine for Parkinson disease in a rural population (TELE-PD)
2007-10	Clinical monitor, site investigator, and steering committee member, cooperative Huntington's observational research trial (COHORT)
2010-2011	Co-chair, publications and data use committee, cooperative Huntington's observational research trial (COHORT)
2009-2011	Steering committee member, randomized, controlled trial of dimebon for Huntington disease (HORIZON)
2007-2012	Steering committee member, randomized controlled trial of rasagiline for restless legs syndrome (RAZE-RLS)
2007-2013	Steering committee member, randomized controlled trial coenzyme Q ₁₀ in individuals with pre-manifest Huntington disease (PREQUEL)
2011-2014	Principal investigator, phase II randomized controlled study of PBT2 for Huntington disease (Reach2HD)
2011-2017	Principal investigator, randomized controlled study of using telemedicine to deliver care in the home of individuals with Parkinson disease (Connect.Parkinson)
2014-present	Co-investigator, mPower, a Parkinson disease smartphone research application and one of the first five such applications released on Apple's ResearchKit in March 2015

EDUCATIONAL ACTIVITIES

Educational Publications

Peer-reviewed publications

Please see research publications numbers 1, 2, 4, and 6.

Editorials

1. **Dorsey ER**, Holloway RG. Quality of life in epilepsy, multiple sclerosis, and beyond. *Ann Neurol* 2007;62:307-8.
2. **Dorsey ER**, Dorsey JA, Dorsey ER. Higher pay. *Virtual Mentor* 2009;11:406-9. Available at: <http://virtualmentor.ama-assn.org/2009/05/oped1-0905.html>.
3. **Dorsey ER**, Meltzer DO. The economics of comparative effectiveness research. *Neurology* 2010;75:492-3.
4. **Dorsey ER**, Nicholson S, Frist WF. Improving the supply and distribution of primary care physicians. *Acad Med* 2011;86:1454-5.
5. Rosenthal LS, **Dorsey ER**. The benefits of exercise in Parkinson disease. *JAMA Neurology* 2013;70:156-7. [PMCID: PMC4122088]
6. **Dorsey ER**, Willis AW. Caring for the majority. *Movement Disorders* 2013;28:261-2.
7. **Dorsey ER**. Choosing wisely – you get what you pay for. *Neurology* 2013;81:946-7.
8. Busis NA, **Dorsey ER**. Shining light on Medicare's values: the Medicare physician data release. *Neurology* 2015;84:1730-1.
9. **Dorsey ER**. Silent majority. *Neurology Clinical Practice* 2016;6:11-13
10. Trister AD, **Dorsey ER**, Friend SH. Smartphones as new tools in the management and understanding of Parkinson's disease. *npj Parkinson's disease* 2016;2:16006. doi: 10.1038/npjparkd.2016.6.
11. **Dorsey ER**. The virtual neurologist. *Neurology* 2017;89:161. doi: 10.1212/WNL.0000000000004097.
12. **Dorsey ER**. A digital journal for a digital era. *Digit Biomark* (epub ahead of print). doi: 10.1159/000458512.

Letters

1. Rutecki GW, **Dorsey ER**, Jarjoura D. Lifestyle as a factor in medical students' career choices. Author reply. JAMA 2003;290:2941-2.
2. Moses H, **Dorsey ER**, Matheson DH, Thier SO. Financial anatomy of biomedical research. Author reply. JAMA 2006;295:1000-1.
3. **Dorsey ER**, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson's disease in the most populous nations, 2005 – 2030. Author reply. Neurology 2007;69:223-4.
4. Holloway RG, Thompson JP, Noyes K, **Dorsey ER**, Schwid SR. A quantitative risk-benefit analysis of natalizumab. Author reply. Neurology 2009;72:1791-2.
5. Grana M, Bull M, Venkataraman V, **Dorsey ER**, Biglan K. Reply: Comparison of office based versus home web-based clinical assessments for Parkinson's disease. Movement Disorders 2012;27:1466.
6. Moses H III, **Dorsey ER**. Funding for biomedical research – reply. JAMA 2013;309:1228-9.
7. Busis NA, **Dorsey ER**. Author response: Shining light on Medicare's values: the Medicare physician data release. Neurology 2015;85:1636.
8. Schneider R, **Dorsey ER**, Biglan K. Telemedicine care for nursing home residents with parkinsonism. J Amer Geriatric Society 2016;64:218-20.
9. **Dorsey ER**, Ritzer G. Author reply: the McDonaldization of medicine. JAMA Neurology 2016;73:479.
10. **Dorsey ER**, Topol EJ. Author reply: State of telehealth. NEJM 2016;375:1400.

Book Chapters

1. **Dorsey ER**, Holloway RG, Ravina BM. Status of biological markers. In Parkinson's disease: clinical diagnosis and management. Second edition. Factor SA, Weiner WJ (eds). Demos: New York. 2008.
2. **Dorsey ER**, Siderowf A, Holloway RG. Economics of Parkinson's disease. In Parkinson's disease: clinical diagnosis and management. Second edition. Factor SA, Weiner WJ (eds). Demos: New York. 2008.
3. **Dorsey ER**, Vitticore P, Moses H. Risks and rewards of biologics for the brain. In the Dana's Foundation Cerebrum 2008: emerging ideas in brain science. Read CA (editor). Dana Press: New York. 2008.
4. **Dorsey ER**. Perspective from a neurologist. In Professionalism in medicine: the case-based guide for medical students. Spandorfer J, Pohl C, Nasca T, and Rattner SL (eds). Cambridge University Press: Cambridge, MA. 2010.
5. Voss T, **Dorsey ER**. Vascular parkinsonism. In: Kompoliti K, Verhagen L, editors. Encyclopedia of Movement Disorders. Oxford: Elsevier Press. 2010.
6. **Dorsey ER**, Shoulson I. Huntington disease: clinical experimental therapeutics. In Frontiers in Neuroscience. Lo DC, Hughes RE (eds). Taylor and Francis Group: Boca Raton, FL. 2011.
7. **Dorsey ER**, Johnston C. Impact of clinical trials in neurology. In Clinical Trials in Neurology. Ravina B, McDermott M, Poole M, Cummings J (eds). Cambridge University Press: Cambridge, UK. 2011.
8. Harris DA, **Dorsey ER**. Telemedicine and Parkinson's disease. In Teleneurology in Practice. Tsao JW, Demaerschalk BM (eds). Springer: New York. 2015.

Institute of Medicine Reports

1. IOM (Institute of Medicine). 2011. (Shoulson I – chair, **Dorsey R** – committee member) Cognitive Rehabilitation Therapy for Traumatic Brain Injury: Evaluating the Evidence. Washington, DC: The National Academies Press.

Working Papers

1. Oster E, Shoulson I, Quaid K, **Dorsey ER** on behalf of the Huntington Study Group PHAROS Investigators. Genetic adverse selection: evidence from long-term care insurance and Huntington disease. National Bureau of Economic Research Working Paper No.15326. September 2009. Available

at www.nber.org/papers/w15326. Featured in NBER Bulletin on Aging and Health 2009;3:6 and The NBER Digest February 2010 available at <http://www.nber.org/digest/feb10/feb10.pdf>.

2. Oster E, Shoulson I, **Dorsey ER**. Optimal expectations and limited medical testing: evidence from Huntington disease. National Bureau of Economic Research Working Paper Number 17629. December 2011. Available at www.nber.org/papers/w17629. Featured in The NBER Digest March 2012 available at <http://www.nber.org/digest/mar12/mar12.pdf>.
3. Oster E, Shoulson I, **Dorsey ER**. Limited life expectancy, human capital and health investments: evidence from Huntington disease. National Bureau of Economic Research Working Paper Number 17931. March 2012. Available at <http://www.nber.org/papers/w17931>.

Conference Proceedings

1. Rajan B, Seidmann A, **Dorsey ER**, Biglan KM, Reminick J. Analyzing the clinical and competitive impact of telemedicine – experience with treating Parkinson disease patients via telemedicine. Proceedings of the 44th Annual Hawaii International Conference on System Sciences, January 11, 2011.

Other Publications

1. **Dorsey R**. Commentary on Placebo response in Parkinson’s disease: comparisons among 11 trials covering medical and surgical interventions by Goetz CG et al. Parkinson’s Disease Monitor & Commentary. 2008;1:4.
2. Tanner CM, Brandabur M, **Dorsey ER**. Parkinson’s disease: a global view. Parkinson Report. April 2008.
3. Deuel L, **Dorsey ER**. Randomized, controlled trial of ethyl-EPA in Huntington disease. The Marker – Huntington’s Disease Society of America, 2009 May: p. 7.
4. Deuel L, **Dorsey ER**. Reporting clinical trial results to research participants in Huntington disease studies. The Marker – Huntington’s Disease Society of America, 2009 May: p. 6, 9.
5. **Dorsey ER**. Equal pay for equal work?. The New Physician 2010;59. Available at <http://www.amsa.org/AMSA/Homepage/Publications/TheNewPhysician/2010/0110Perspectives.aspx>.
6. Adams J, Tarolli C, **Dorsey ER**. Next generation house call. Cerebrum. 2017;pii: cer-02-17. eCollection 2017 Jan-Feb. Available at: http://www.dana.org/Cerebrum/2017/Next_Generation_House_Call/
7. **Dorsey R**, Topol E. Here’s what your future doctor visits could look like. Fortune. May 2, 2017. Available at: <http://fortune.com/2017/05/02/brainstorm-health-2017/>.

Teaching

2005	Small group leader, Neuroanatomy Course, first year medical students, University of Pennsylvania School of Medicine (two month course for ~15 students)
2006-08	Small group co-leader, Ambulatory Clerkship Journal Club, second year medical students, University of Rochester School of Medicine (one month course with ~12 lectures for ~12 students)
2008	Lecturer, Academic Career Development Course, geriatric fellows, University of Rochester School of Medicine (2 lectures for ~10 fellows)
2008-10	Lecturer, Process of Discovery Course, second and fourth year medical students, University of Rochester School of Medicine (2 lectures per year for ~100 medical students per lecture)
2008-10	Lecturer, Academic Research Track, first year medical students, University of Rochester School of Medicine (1 lecture per year for ~20 students)
2010-2013	Lecturer, Diseases and disorders of the nervous system, undergraduate neuroscience majors, Johns Hopkins University (1 lecture per year for ~50 students)
2010-2012	Lecturer, Discovery to Market, Johns Hopkins Carey Business School (2 lectures per year for ~80 students)

2014-2016	Lecturer, Practical Skills in Grant Writing, University of Rochester School of Medicine (1 lecture per year for ~15 students)
2014-present	Lecturer, Process of Discovery Course, second and fourth year medical students, University of Rochester School of Medicine (1 lecture per year for ~100 medical students per lecture)
2014-present	Lecturer, Simon School of Business in medical management and related courses (2 lectures per year, ~50 students per lecture)
2015	Policy panelist, public health sciences course, University of Rochester Medical Center (1 panel, ~50 students)

Mentoring

2006-present Mentor to undergraduate, public health, medical students, and residents. Over 10 students have published their first peer-reviewed paper under my mentorship including 6 in *JAMA*.

Student	Position when mentored	Accomplishments	Current position
Joel P. Thompson, MD, MPH	Public health student, University of Rochester, 2006-2009	<ul style="list-style-type: none"> Published 8 papers together, including in <i>JAMA</i> Received American Academy of Neurology summer fellowship Completed MPH and matriculated into medical school 	Radiology fellow, Johns Hopkins
Phil Vitticore, MD	Neurology resident, University of Rochester, 2006-2007	<ul style="list-style-type: none"> Published two papers together 	Neurologist in private practice in upstate New York
Melissa Carrasco, PhD	MD/PhD student at University of Rochester	<ul style="list-style-type: none"> Published two papers together Selected for sanofi-aventis Minority Scholars Program 	Pediatric neurology resident, University of Maryland/Johns Hopkins Medicine
Jason de Roulet, MD	Medical student at University of Rochester, 2006-2009	<ul style="list-style-type: none"> Taught as student in ambulatory clerkship journal club Published three papers together, including in <i>JAMA</i> 	Gastroenterology fellow, Case Western Reserve
Lisa Deuel, MD	Research assistant, 2007-2010	<ul style="list-style-type: none"> Published five papers together 	Neurology resident, Albany Medical Center
E.J. Dayoub, MD, MPP	University of Rochester undergraduate, 2007-2009	<ul style="list-style-type: none"> Published two papers together 	Medicine resident, University of Pennsylvania
Ben George, MD, MPH	University of Rochester undergraduate, Johns Hopkins Public Health student, UR medical student, UR neurology resident, 2007-present	<ul style="list-style-type: none"> Published eight papers together, including in <i>JAMA</i> Received four extramural funded scholarships, including from American Academy of Neurology and National Institute on Aging Completed MPH at Bloomberg School of Public 	Neurology resident, University of Rochester

		Health at Johns Hopkins <ul style="list-style-type: none"> • Won two business plan competitions 	
Jun Mitsumoto, MD MPH	Medical student, Columbia University, 2008	<ul style="list-style-type: none"> • Published paper in <i>Annals of Neurology</i> 	Family practitioner, New York City
Alex Gangler Wright, MD	Research assistant, Johns Hopkins, 2010-2011	<ul style="list-style-type: none"> • Helped expand telemedicine program 	Radiology resident, UCSF
Kristin Darwin	Research assistant, Johns Hopkins, 2011-13	<ul style="list-style-type: none"> • Published multiple papers 	Ob/gyn resident, Johns Hopkins
Vinayak Venkataraman	Research assistant, Johns Hopkins, 2011-13	<ul style="list-style-type: none"> • Published multiple papers 	Medicine/pediatrics resident, Massachusetts General Hospital
Paige Nichols	Research assistant, Johns Hopkins, 2011-13	<ul style="list-style-type: none"> • Published multiple papers 	Medical student, Johns Hopkins
Meredith Achey	Research assistant, University of Rochester, 2013-15	<ul style="list-style-type: none"> • Published two papers • Coordinated national telemedicine study 	Medical student, Duke University
Denzil Harris	Research assistant, University of Rochester, 2013-15	<ul style="list-style-type: none"> • Published paper • Coordinated global smartphone study 	Medical student and Dean's Scholar, University of Rochester
Ryan Korn	Research assistant, University of Rochester, 2014-16	<ul style="list-style-type: none"> • Published multiple papers • Coordinated multi-center telemedicine study 	Medical student, University of Rochester
William Zhu	Research assistant, University of Rochester, 2015-16	<ul style="list-style-type: none"> • Published multiple papers • Coordinated multi-center telemedicine study 	Medical student, University of Michigan
Solomon Abiola, MS	Research associate, University of Rochester, 2014-2015	<ul style="list-style-type: none"> • Supported development of smartphone applications 	Computer science and translational medicine PhD student, University of Rochester
Steven Goldenthal	Research assistant, University of Rochester, 2016-17	<ul style="list-style-type: none"> • Published multiple papers 	Medical student, University of Michigan
Molly Elson	Research assistant, University of Rochester, 2016-17	<ul style="list-style-type: none"> • Published multiple papers 	Medical student, Emory University
Mulin Xiong	Research assistant, University of Rochester, 2016-17	<ul style="list-style-type: none"> • Published multiple papers 	Medical student, Michigan State University

2007-2010 Fellowship director, Experimental Therapeutics Program, University of Rochester.

Fellow	Current Position
David Shprecher, MD, MPH	Assistant Professor of Neurology, University of Utah
Tiffini Voss, MD, MPH	Now at Merck, previously Assistant Professor of Neurology, University of Virginia

2010-2013 As division director, I oversaw the fellowship program director and fellows at Johns Hopkins.

Fellow	Current position
Liana Rosenthal, MD	Assistant Professor in Neurology, Johns Hopkins Medicine
Chizoba Umeh, MD	Instructor in Neurology, Brigham and Women's Hospital

2013 Mentor to six Wharton MBA students for their Field Application Program related to telemedicine

Thesis Committee Member

2006 Master's degree in public health, thesis committee member for Joel P. Thompson

2008-11 Master's degree in public health, thesis committee member for David Shprecher, DO

Training Grant Participation

2007-10 Fellowship director, NIH-funded T32 Experimental Therapeutics Fellowship (~2 fellows per year)

Educational Program Building/Leadership

2010-2011 Co-founder (with Professor Avi Seidmann) and lecturer, Medical Entrepreneurship Course, University of Rochester School of Medicine and Simon School of Business. Course was an elective for ~20 medical and business school students who as part of the course created and presented their own business plan for improving health care.

CLINICAL ACTIVITIES

Certification

Licensed Physician, State of Maryland. License# D0070841, expires 9/30/18.

Licensed Physician, State of New York. License# 237341-1, expires 2/28/19.

Licensed Physician, State of California. License# A105458, expires 3/31/18.

Licensed Physician, State of Florida. License# ME 110875, expires 1/31/18.

Licensed Physician, State of Delaware. License #C1-0009916, expires 3/31/19.

Certified, Human Subject Protection Program (HSPP) 2005. HSPP# 40260810.

Diplomate, American Board of Psychiatry and Neurology, Inc., May 14, 2006.

Clinical Responsibilities

2006-10 Neurology inpatient and consult attending at Strong Memorial Hospital (4 weeks per year)

2006-10 Neurology attending in movement disorder clinic at the University of Rochester (1 day per week)

2010-2013 Neurology inpatient and consult attending at Johns Hopkins Hospital (4-6 weeks per year)

2010-2013 Neurology attending in movement disorder clinic at Johns Hopkins (1 day per week)

2010-2013 Neurology specialist for telemedicine consultation (1/2 day per week)

2013-2016 Neurology consult attending at Strong Memorial Hospital (2 weeks per year)

2013-present Neurology specialist for telemedicine consultations nationally (~1 day per week)

Clinical Program Building/Leadership

2007-present Co-founder (with Dr. Kevin Biglan) of a telemedicine program to deliver specialty care to individuals with Parkinson disease and other movement disorders in nursing homes and in their homes – "virtual house calls." Program has provided care to patients in nursing homes, satellite clinics, and residences of patients in five states and 20+ countries on six continents.

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

2014-2017 Member, Medical School Advisory Council (promotions and tenure)

National/Global Administrative Appointments

2002-03 Member, Board of Directors, National Depressive and Manic Depressive Association (now Depression and Bipolar Support Alliance)

2003-04 Member, Finance subcommittee, Depression and Bipolar Support Alliance

2005 Intern to CEO of University of Pennsylvania Health System (Mr. Ralph Mueller), improving patient access

2008-2013 Member, Parkinson Disease Expert Group, World Health Organization, to help determine the global burden of Parkinson disease

2008-2012 Executive Committee member, Huntington Study Group

2008-2014 Director, Huntington Study Group Coordination Center

2009-2013 Member, American Academy of Neurology Investment Committee

2012-2014 Chair, Movement Disorders Society Task Force on Telemedicine

2012-2014 Treasurer, Huntington Study Group

2013 – 2016 Huntington Disease Society of America, Scientific Advisory Board

2014 – present Chair (elected), Huntington Study Group, a global research network of 400+ investigators at 100+ research sites principally in Australia, Canada, and United States that seeks to find treatments that make a difference in Huntington disease

Journals

Founder

Founder and editor of *HD Insights*, a Huntington disease research periodical that reaches ~3000 investigators in academia and industry globally, 2012 – present

Founding editor, *Digital Biomarkers* (publisher: Karger Publishers: Basel, Switzerland), 2017 – present

Editorial boards

Inaugural member of *Journal of Huntington's Disease*, 2012 – present

Ad hoc reviewer

Medical journals	Neurology journals	Health economics/policy journals
<i>Academic Medicine</i>	<i>Annals of Neurology</i>	<i>Applied Health Economics and Health Policy</i>
<i>Archives of General Psychiatry</i>	<i>European Journal of Neurology</i>	<i>Health Affairs</i>
<i>Annals of Internal Medicine</i>	<i>JAMA Neurology</i>	<i>Journal of Health Politics, Policy and Law</i>
<i>Archives of Internal Medicine</i>	<i>Journal of Parkinson's Disease</i>	<i>Value in Health</i>
<i>JAMA</i>	<i>Lancet Neurology</i>	
<i>Journal of Clinical Investigation</i>	<i>Movement Disorders</i>	
<i>Journal of General Internal Medicine</i>	<i>Neuroepidemiology</i>	
<i>Pediatrics</i>	<i>Neurology</i>	
<i>PLoS One</i>	<i>Parkinsonism & Related Disorders</i>	

Grant Peer Review

September 26, 2007 Michael J. Fox Foundation for Parkinson's Research, Clinical Discovery Grants 2007.
August 13, 2008 Michael J. Fox Foundation for Parkinson's Research, Clinical Intervention Awards 2008
July 26, 2009 Parkinson's Disease Society of the United Kingdom, Project Grants, 2009.
August 31, 2009 The Wellcome Trust, Post-doctoral fellowships.
October 13, 2009 Michael J. Fox Foundation for Parkinson's Research, Biomarkers Review 2009.
November 2-3, 2009 National Institute for Neurological Disorders and Stroke Clinical Trials Study Section (NSD-K),
ad hoc reviewer
2010 – 2013 American Academy of Neurology Foundation Clinical Research Training Fellowship, member
of review committee

Federal Service

October 8, 2010 Ad hoc panel member, U.S. Food and Drug Administration, Neurological Devices Advisory Panel
January – Nov 2011 Committee member, Institute of Medicine Committee on Cognitive Rehabilitation Therapy for
Traumatic Brain Injury
2012 – present Member, Food and Drug Administration, Neurological Devices Panel of the Medical Devices
Advisory Committee

Professional Society Membership

2009-2011 Member, American Society for Experimental Neurotherapeutics
2007-present Member, Movement Disorders Society
2007-present Member, American Academy of Neurology

Conference Organizer

2008 Co-chair, Huntington Study Group Site Management Course, St. Pete Beach, Florida
2008-09 Program committee, Robert Wood Johnson Foundation Physician Faculty Scholars 2008
and 2009 national meetings
2014-present Co-founded (with Professor Avi Seidmann), d.health Summit (www.dhealthsummit.org)
that convenes annually in New York City ~200 leaders in policy, technology, and health to
foster disruptive care models for aging Americans

Consultancies

2005-07 Strategic advisor, Avid Radiopharmaceuticals, Inc.
2009-10, 2012 Consultant to Medtronic
2009-2013 Consultant to Lundbeck, Inc.
2012 Consultant to National Institute for Neurological Disorders and Stroke (Dr. Walter
Koroshetz, Deputy Director) to conduct evaluation of a 10-year stroke program called
SPOTRIAS
2014-15 Consultant to National Institute for Neurological Disorders and Stroke (Dr. Walter
Koroshetz, Deputy Director) to conduct evaluation of a 10-year neurological emergency
treatment trials (NETT) network
2012-present Consultant to Clintrex
2012-present Member of Medical Advisory Board, Grand Rounds, an online second opinion service

RECOGNITION

Awards

1998 Director's List, The Wharton School
1999 Dr. Eric C. Raps' Memorial Award for Excellence in Clinical Neurology, University of Pennsylvania School
of Medicine

2002 Intern of the Year, Evanston Hospital, Evanston Northwest Healthcare
2005 Education Research Award, Department of Neurology, University of Pennsylvania Medical Center
2006 American Academy of Neurology Clinical Research Training Fellowship
2007 Mentor to Melisa Carrasco, recipient of sanofi-aventis Minority Scholars Program
2007 George Engel/John Romano Dean's Teaching Fellow
2008 Robert Wood Johnson Foundation Physician Faculty Scholar
2009 *Academic Medicine* Excellence in Reviewing Award
2010 American Academy of Neurology's Jon Stolk Award in Movement Disorders for Young Investigators
2011 Elected to American Neurological Association
2015 White House "Champion for Change" for Parkinson's disease
2015 Top 5 most popular papers, *JAMA*
2015 Top 3 most talked about article, *JAMA Neurology*
2016 *Rochester Business Journal* Health Care Achievement Award in Health Care Innovation
2016 Burroughs Wellcome Fund Innovators in Regulatory Science Award recipient